Please use this identifier to cite or link to this item: http://hdl.handle.net/10311/1827
Title: Incidence of diabetes mellitus‑related comorbidities among patients attending two major HIV clinics in Botswana: a 12‑year retrospective cohort study
Authors: Rankgoane‑Pono, Goabaone
Tshikuka, Jose Gaby
Magafu, Mgaywa Gilbert Mjungu Damas
Masupe, Tiny
Molefi, Mooketsi
Hamda, Shimeles Genna
Setlhare, Vincent
Tapera, Roy
Mbongwe, Bontle
Keywords: Incidence
diabetes-related comorbidities
combination antiretroviral therapy
PLHIV
Botswana
Issue Date: 1-Feb-2018
Publisher: BioMed Central, www.biomedcentral.com
Citation: Rankgoane‑Pono, G. et a.l (2018) Incidence of diabetes mellitus‑related comorbidities among patients attending two major HIV clinics in Botswana: a 12‑year retrospective cohort study. BMC Research Notes. Vol. 11, No. 90. pp. 1-5
Abstract: Objectives: Exposure to combination antiretroviral therapy (cART) is associated with the development of diabetes mellitus related comorbidities (DRCs). This study aims to: (i) estimate the incidence of DRCs among cART recipients, (ii) assess the time-to-event (development of DRC) and, (iii) compare survival function between recipients on first-line regimen and those on second-, third-line cART regimen. Results: The incidence of DRCs was 26.8/1000 person-years, with total time of exposure of 3316 person-years. The average time to event for all the three regimens was 11.72 ± 0.20 years. The first-line cART regimen had a shorter mean ± SE of 10.59 ± 0.26 years to the event compared to 12.69 ± 0.24 years for the second-, third-line cART regimen. Recipients on the first-line had a shorter survival than recipients on second-, third-line cART (Log-rank X2 = 8.98, p < 0.003). Data from this study showed that the risk of developing DRCs per year of exposure was significantly greater for patients on first-line compared to those who were on second-, third-line regimen; which, suggests that monitoring of cART long-term side effects and regular reviewing of cART regimens is important. Meticulous selection of drug combinations is a key to improving recipients’ survival.
URI: http://hdl.handle.net/10311/1827
ISSN: 1756-0500
Appears in Collections:Research articles (School of Medicine)

Files in This Item:
File Description SizeFormat 
Rankgoane‑Pono_BMCRN_2018.pdf670.36 kBAdobe PDFThumbnail
View/Open


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.